Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyClover Health Breyanzi Prior Auth Policy | OpenPay…
    Ask Trek AI about this page
    CurrentClover HealthPolicy 4514-A

    Standard Medicare Part B Management Breyanzi

    Customize your policy alerts

    Sign up for clover_health Policy 4514-A alerts

    Get alerted when Policy 4514-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Medicare Part B coverage for Breyanzi in members with specified B-cell lymphomas, chronic lymphocytic leukemia or small lymphocytic lymphoma, Richter transformation, and selected compendial indications. Coverage requires applicable disease, prior-treatment, age, response, and clinical eligibility criteria, with a typical authorization of 3 months for one dose.

    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Breyanzi
    Policy CodePolicy 4514-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation showing that the applicable coverage criteria are met before treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3 monthsTypical authorization duration
    1 doseDoses authorized
    18 yearsAdult eligibility threshold
    ECOG ≥3Performance-status exclusion

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6
    Compendial-use categories

    Medical Necessity and Eligibility Criteria

    Adult Large B-cell Lymphomas

    Authorization of 3 months (one dose) may be granted for treatment of B-cell lymphomas in members 18 years of age or older when any one of the following criteria pathways is met.

    ONE of the following

    • ALL of the following

      • The member has received prior treatment with two or more lines of systemic therapy.
      • The member has any of the following B-cell lymphoma subtypes

        • Diffuse large B-cell lymphoma (DLBCL), including DLBCL not otherwise specified (NOS), follicular lymphoma grade 3B, or DLBCL arising from indolent lymphomas.
        • High-grade B-cell lymphoma, including high-grade B-cell lymphoma with translocations of MYC and BCL2 and/or BCL6 (double/triple hit lymphoma), or high-grade B-cell lymphoma NOS.
        • Primary mediastinal large B-cell lymphoma.
        • Follicular lymphoma.
        • HIV-related B-cell lymphomas, including HIV-related DLBCL, primary effusion lymphoma, HHV8-positive diffuse large B-cell lymphoma NOS, or plasmablastic lymphoma.
        • Monomorphic post-transplant lymphoproliferative disorder (B-cell type).
    • ALL of the following

      • The member has received prior treatment with first-line chemoimmunotherapy.
      • The member has relapsed/refractory disease.
      • The member has any of the following B-cell lymphoma subtypes

        • Diffuse large B-cell lymphoma (DLBCL), including DLBCL not otherwise specified (NOS), follicular lymphoma grade 3, or DLBCL arising from indolent lymphomas.
        • High-grade B-cell lymphoma, including high-grade B-cell lymphoma with translocations of MYC and BCL2 and/or BCL6 (double/triple hit lymphoma), or high-grade B-cell lymphoma NOS.
        • Primary mediastinal large B-cell lymphoma.
    • ALL of the following

      • The member has received prior treatment with a covalent Bruton tyrosine kinase inhibitor, such as acalabrutinib (Calquence), ibrutinib (Imbruvica), or zanubrutinib (Brukinsa).
      • The member has relapsed/refractory mantle cell lymphoma.

    Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

    Authorization of 3 months (one dose) may be granted for treatment of relapsed or refractory CLL/SLL in members 18 years of age or older when all of the following therapy requirements are met.

    ALL of the following

    • The member has relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
    • The member has received prior therapy with a Bruton tyrosine kinase inhibitor-containing regimen, such as acalabrutinib (Calquence), ibrutinib (Imbruvica), or zanubrutinib (Brukinsa).
    • The member has received prior therapy with a BCL-2 inhibitor-containing regimen, such as venetoclax.

    Histologic (Richter) Transformation to DLBCL

    Authorization of 3 months (one dose) may be granted for treatment of histologic (Richter) transformation to DLBCL, whether clonally related or of unknown clonal status, when all of the following criteria are met.

    ALL of the following

    • The member has histologic (Richter) transformation to diffuse large B-cell lymphoma (DLBCL), with clonal status either clonally related or unknown.
    • The member has at least one of the following

      • del(17p)/TP53 mutation.
      • Chemotherapy-refractory disease.
      • The member is unable to receive chemoimmunotherapy.

    Pediatric Primary Mediastinal Large B-cell Lymphoma

    Authorization of 3 months (one dose) may be granted for treatment of relapsed/refractory primary mediastinal large B-cell lymphoma in members less than 18 years of age when all of the following criteria are met.

    ALL of the following

    • The member is less than 18 years of age.
    • The member has relapsed/refractory primary mediastinal large B-cell lymphoma.
    • The member has received prior therapy with at least two prior chemoimmunotherapy regimens.
    • The member achieved a partial response.

    Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma.

    Coverage will not be provided for members with a previous treatment course with the requested medication or another CD19-directed chimeric antigen receptor (CAR) T-cell therapy.

    Coverage will not be provided for members with an ECOG performance status greater than or equal to 3. This means the member is not ambulatory and not capable of all self-care and is confined to bed or chair more than 50% of waking hours.

    Coverage will not be provided for members with inadequate and unstable kidney, liver, or cardiac function.

    Coverage will not be provided for members with active hepatitis B, active hepatitis C, or any active uncontrolled infection.

    Coverage will not be provided for members with active graft-versus-host disease or an active inflammatory disorder.

    Authorization and Documentation Requirements

    Prior Authorization

    Three-Month, One-Dose Authorization

    Prior authorization is required. Authorization for 3 months (one dose) may be granted when the applicable coverage criteria are met.

    • CLL/SLL: Member is 18 years or older with relapsed or refractory disease and has received Bruton tyrosine kinase (BTK) inhibitor- and BCL-2 inhibitor-containing regimens.
    • Histologic (Richter) transformation to DLBCL: Member has del(17p)/TP53 mutation, is chemotherapy refractory, or is unable to receive chemoimmunotherapy.
    • Pediatric primary mediastinal large B-cell lymphoma: Member is younger than 18 years, has relapsed/refractory disease, received at least two prior chemoimmunotherapy regimens, and achieved partial response.
    Documentation Required

    Document Previous Treatment Failure

    For all submissions, chart notes or medical-record documentation must be available upon request to demonstrate failure of previous lines of therapy.

    Therapy Overview

    Breyanzi (lisocabtagene maraleucel) is a CD19-directed CAR T-cell therapy used for selected relapsed, refractory, or multiply treated B-cell malignancies. Coverage applies to specified FDA-approved indications and Medicare-approved compendial uses, subject to disease-specific prior-treatment and clinical eligibility criteria.

    Clinical Definitions

    ECOG performance status greater than or equal to 3
    TermECOG performance status greater than or equal to 3
    Functional statusNot ambulatory and not capable of all self-care
    Time confined to bed or chairMore than 50% of waking hours
    Refractory or relapsed disease
    Refractory diseaseDisease that does not respond to therapy
    Relapsed diseaseDisease that returns after therapy
    Policy wordingRelapsed/refractory disease

    Prior-Line and Salvage Therapy Requirements

    Salvage Therapy Requirement — Adult Large B-Cell Lymphoma

    The applicable salvage-therapy pathway must be met:

    Adult prior-therapy pathways

    • The member has received prior treatment with two or more lines of systemic therapy and has an eligible B-cell lymphoma subtype.>=2 prior systemic therapy lines
    • The member has received prior first-line chemoimmunotherapy and has relapsed or refractory disease with an eligible B-cell lymphoma subtype.Prior first-line chemoimmunotherapy with relapsed/refractory disease
    • The member has received prior treatment with a covalent Bruton tyrosine kinase inhibitor and has relapsed or refractory mantle cell lymphoma.Prior covalent BTK inhibitor for mantle cell lymphoma

    Disease Biology and Biomarker Criteria

    del(17p)/TP53 mutation
    Required biomarkerPresence of del(17p)/TP53 mutation
    Applicable pathwayHistologic (Richter) transformation to DLBCL, clonally related or with unknown clonal status
    ExceptionThe mutation requirement may be met by chemotherapy-refractory disease or inability to receive chemoimmunotherapy
    MYC and BCL2 and/or BCL6 translocations
    TranslocationsMYC and BCL2 and/or BCL6
    Lymphoma classificationHigh-grade B-cell lymphoma
    Named subtype

    Covered Breyanzi Indications

    ProductCovered use
    Breyanzi (lisocabtagene maraleucel)Specified FDA-approved and Medicare-approved compendial B-cell malignancies when applicable policy criteria are met
    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Breyanzi
    Policy CodePolicy 4514-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation showing that the applicable coverage criteria are met before treatment.
    SourceLink
    On This Page
    Medical Necessity and Eligibility CriteriaAuthorization and Documentation RequirementsTherapy OverviewClinical DefinitionsPrior-Line and Salvage Therapy RequirementsDisease Biology and Biomarker CriteriaCovered Breyanzi Indications
    HIV-related B-cell lymphomas, including HIV-related DLBCL, primary effusion lymphoma, HHV8-positive diffuse large B-cell lymphoma NOS, or plasmablastic lymphoma.
  1. Monomorphic post-transplant lymphoproliferative disorder (B-cell type).
  2. Documentation Required

    Submit Compendial Support

    For indications other than those listed in the policy, submit supporting evidence from Medicare-approved compendia with the authorization request.

    • HIV-related B-cell lymphomas
    • Monomorphic post-transplant lymphoproliferative disorder (B-cell type)
    • Pediatric primary mediastinal large B-cell lymphoma
    • Mantle cell lymphoma
    • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    • Histologic (Richter) transformation to diffuse large B-cell lymphoma (DLBCL)
    Denial Risk

    Exclusion Criteria

    Coverage will not be provided when any of the following exclusion criteria apply.

    • Previous treatment course with the requested medication or another CD19-directed chimeric antigen receptor (CAR) T-cell therapy.
    • ECOG performance status greater than or equal to 3; the member is not ambulatory or capable of all self-care and is confined to bed or chair more than 50% of waking hours.
    • Inadequate and unstable kidney, liver, or cardiac function.
    • Active hepatitis B, active hepatitis C, or any active uncontrolled infection.
    • Active graft-versus-host disease.
    • Active inflammatory disorder.
    Denial Risk

    Primary CNS Lymphoma Excluded

    Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma.

    Note

    Unlisted Indications

    Indications outside those listed in this policy are assessed on an individual basis and require supporting evidence from Medicare-approved compendia.

    CD19-directed CAR T-cell therapy
    Full termChimeric antigen receptor T-cell therapy
    TargetDirected against the CD19 antigen
    Policy examplePrevious treatment with another CD19-directed CAR T-cell therapy excludes coverage

    Salvage Therapy Requirement — Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    The following salvage-therapy requirements must be met:

    CLL/SLL prior therapy: The member has relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after prior therapy with both a Bruton tyrosine kinase inhibitor-containing regimen and a BCL-2 inhibitor-containing regimen.At least one BTK inhibitor-containing regimen and one BCL-2 inhibitor-containing regimen

    Salvage Therapy Requirement — Pediatric Primary Mediastinal Large B-Cell Lymphoma

    The following salvage-therapy requirements must be met:

    Pediatric primary mediastinal large B-cell lymphoma prior therapy: The member has relapsed or refractory primary mediastinal large B-cell lymphoma after receiving at least two prior chemoimmunotherapy regimens and achieving a partial response.>=2 prior chemoimmunotherapy regimens; partial response
    Double/triple-hit lymphoma